Noxopharm Ltd has released a press release.
First SOF-SKN dose in HERACLES clinical trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- Promising Sofra results from overseas company
- Green light for HERACLES clinical trial
- New funds from Nyrada share sales
- March 2025 Quarterly Activities Report and Appendix 4C
- Appendix 4D and FY2025 Half Year Financial Report
Later from Noxopharm
- HERACLES clinical trial - Update 1
- June 2025 Quarterly Activities Report and Appendix 4C
- US company demonstrates strong Sofra potential
- HERACLES clinical trial Update 2
- HERACLES clinical trial Update 3
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm